Improvement of brucellosis prevention : development of a vaccine and a serologic test using different recombinant antigens to discriminate vaccinated from infected animals

Projektinformationen

ID Finanzhilfevereinbarung: AGRE0049

Projekt abgeschlossen

Startdatum 1 April 1991

Enddatum 31 März 1995

Finanziert unter

• First multiannual programme (EEC) for biotechnology-based agro-industrial research and technological development (ECLAIR), 1988-1993

Gesamtkosten

Keine Daten

EU-Beitrag

Keine Daten

Koordiniert durch

INNOGENETICS
Belgium

CORDIS bietet Links zu öffentlichen Ergebnissen und Veröffentlichungen von HORIZONT-Projekten.

Links zu Ergebnissen und Veröffentlichungen von RP7-Projekten sowie Links zu einigen Typen spezifischer Ergebnisse wie Datensätzen und Software werden dynamisch von OpenAIRE abgerufen.

Verwertbare Ergebnisse

Brucellosis vaccine and serological test development

The aim of this research project has been the development of a new vaccine based on the knowledge of the pathogenesis of the Brucellosis bacteria and on the new technologies in the field of molecular genetics and immunology. Simultaneously, a diagnostic tool is being developed that will allow the differential diagnosis between animals treated with the new developed vaccine and infected animals.To achieve these goals Brucella protein antigens have been produced by recombinanat DNA techniques and their performance in serology has been evaluated. In parallel,presently available vaccine strains have been deleted in the genes encoding these diagnostic important proteins to avoid seroconversion upon vaccination. The strains have been studied in the mouse model to determine the residual virulence and to evaluate the protective effect upon challenge with a virulent Brucella strain. These experiments have yield encouraging results which warrent the furthur exploration of this vaccination and serology coupled system in a target animal like sheep or goats.